CSF1
CSF1 (Macrophage colony-stimulating factor 1) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Tenosynovial giant cell tumour.
Overview
Cytokine that plays an essential role in the regulation of survival, proliferation and differentiation of haematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. Promotes the release of pro-inflammatory chemokines, and thereby plays an important role in innate immunity and in inflammatory processes. Plays an important role in the regulation of osteoclast proliferation and differentiation, the regulation of bone resorption, and is required for normal bone development.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Pexidartinib. In OnCo, 3 product records name it (Vimseltinib, Pexidartinib and Surufatinib).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CSF1 (Macrophage colony-stimulating factor 1) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Tenosynovial giant cell tumour.
- 1 · What it is
CSF1 (Macrophage colony-stimulating factor 1) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Tenosynovial giant cell tumour.
- 2 · What goes wrong in cancer
Cytokine that plays an essential role in the regulation of survival, proliferation and differentiation of haematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes.
- 3 · How drugs use it
No product in this corpus aims at CSF1 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:2432 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P09603 (protein name, function text, keywords and locations (REST API)); CIViC gene CSF1 (1 evidence items, 0 assertions, 1 variants; diseases: Tenosynovial Giant Cell Tumour (GraphQL API, CC0))
Biology
Cytokine that plays an essential role in the regulation of survival, proliferation and differentiation of haematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. Promotes the release of pro-inflammatory chemokines, and thereby plays an important role in innate immunity and in inflammatory processes. Plays an important role in the regulation of osteoclast proliferation and differentiation, the regulation of bone resorption, and is required for normal bone development. Required for normal male and female fertility. Promotes reorganisation of the actin cytoskeleton, regulates formation of membrane ruffles, cell adhesion and cell migration. Plays a role in lipoprotein clearance. Location: Cell membrane; Secreted, extracellular space (UniProt). Locus 1p13.3 (HGNC).
- Tenosynovial giant cell tumour: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 1 clinical evidence items on its variants. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"CSF1" OR ABSTRACT:"CSF1" OR TITLE:"colony stimulating factor 1" OR ABSTRACT:"colony stimulating factor 1" OR TITLE:"Macrophage colony-stimulating factor 1" OR ABSTRACT:"Macrophage colony-stimulating factor 1" OR TITLE:"M-CSF" OR ABSTRACT:"M-CSF" OR TITLE:"MGC31930" OR ABSTRACT:"MGC31930") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CSF1, not a curated reading list.
Similar pages
not linked directly; found by shared links- TrialMOTION
- TrialA Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT
- TrialStudy of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
- Key paperPexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
- TargetCSF1R
Shares Surufatinib, Vimseltinib, Pexidartinib, Myeloid suppression: TAMs, MDSCs & don't-eat-me signals.
- TrialENLIVEN
- CompanyDeciphera Pharmaceuticals (Ono)